Switch to:
Also traded in: France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
ABBV's Cash to Debt is ranked higher than
69% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. ABBV: N/A )
Ranked among companies with meaningful Cash to Debt only.
ABBV' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 0.66 Max: No Debt
Current: N/A
Equity to Asset 0.07
ABBV's Equity to Asset is ranked lower than
97% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ABBV: 0.07 )
Ranked among companies with meaningful Equity to Asset only.
ABBV' s Equity to Asset Range Over the Past 10 Years
Min: 0.05  Med: 0.13 Max: 0.69
Current: 0.07
0.05
0.69
Interest Coverage 10.33
ABBV's Interest Coverage is ranked lower than
66% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.94 vs. ABBV: 10.33 )
Ranked among companies with meaningful Interest Coverage only.
ABBV' s Interest Coverage Range Over the Past 10 Years
Min: 7.95  Med: 5027.47 Max: 9999.99
Current: 10.33
7.95
9999.99
F-Score: 7
Z-Score: 2.30
M-Score: -2.14
WACC vs ROIC
12.31%
31.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 34.18
ABBV's Operating margin (%) is ranked higher than
94% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.77 vs. ABBV: 34.18 )
Ranked among companies with meaningful Operating margin (%) only.
ABBV' s Operating margin (%) Range Over the Past 10 Years
Min: 17.09  Med: 30.15 Max: 34.7
Current: 34.18
17.09
34.7
Net-margin (%) 23.03
ABBV's Net-margin (%) is ranked higher than
90% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. ABBV: 23.03 )
Ranked among companies with meaningful Net-margin (%) only.
ABBV' s Net-margin (%) Range Over the Past 10 Years
Min: 8.89  Med: 24.35 Max: 32.62
Current: 23.03
8.89
32.62
ROE (%) 157.08
ABBV's ROE (%) is ranked higher than
99% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. ABBV: 157.08 )
Ranked among companies with meaningful ROE (%) only.
ABBV' s ROE (%) Range Over the Past 10 Years
Min: 24.85  Med: 56.91 Max: 105.11
Current: 157.08
24.85
105.11
ROA (%) 12.68
ABBV's ROA (%) is ranked higher than
85% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. ABBV: 12.68 )
Ranked among companies with meaningful ROA (%) only.
ABBV' s ROA (%) Range Over the Past 10 Years
Min: 6.25  Med: 16.89 Max: 39.54
Current: 12.68
6.25
39.54
ROC (Joel Greenblatt) (%) 249.00
ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 757 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.44 vs. ABBV: 249.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABBV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 74.13  Med: 142.15 Max: 170.07
Current: 249
74.13
170.07
Revenue Growth (3Y)(%) 3.90
ABBV's Revenue Growth (3Y)(%) is ranked higher than
51% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. ABBV: 3.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABBV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.90 Max: 5.7
Current: 3.9
0
5.7
EBITDA Growth (3Y)(%) -10.50
ABBV's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. ABBV: -10.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABBV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -10.50 Max: 2.2
Current: -10.5
0
2.2
EPS Growth (3Y)(%) -20.30
ABBV's EPS Growth (3Y)(%) is ranked lower than
65% of the 501 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. ABBV: -20.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABBV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -20.30 Max: -1
Current: -20.3
» ABBV's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

ABBV Guru Trades in Q2 2015

First Eagle Investment 678,300 sh (New)
Louis Moore Bacon 25,000 sh (New)
Steven Cohen 1,245,500 sh (+760.15%)
Larry Robbins 17,855,941 sh (+630.71%)
David Dreman 28,292 sh (+193.03%)
Scott Black 151,910 sh (+27.14%)
Pioneer Investments 2,701,617 sh (+14.08%)
Tom Russo 86,718 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Louis Moore Bacon 100,000 sh (unchged)
Jeff Auxier 19,171 sh (unchged)
Westport Asset Management Sold Out
Manning & Napier Advisors, Inc Sold Out
Murray Stahl 32,060 sh (-0.01%)
Ken Fisher 1,006,679 sh (-0.40%)
Mairs and Power 268,776 sh (-1.19%)
Mario Gabelli 46,562 sh (-1.38%)
Dodge & Cox 34,255 sh (-2.28%)
Lee Ainslie 3,950 sh (-8.56%)
NWQ Managers 1,583,682 sh (-13.88%)
PRIMECAP Management 2,799,320 sh (-24.97%)
Paul Tudor Jones 6,500 sh (-35.45%)
Joel Greenblatt 33,605 sh (-93.95%)
Jim Simons 8,200 sh (-99.31%)
» More
Q3 2015

ABBV Guru Trades in Q3 2015

Jim Simons 2,933,756 sh (+35677.51%)
Paul Tudor Jones 49,480 sh (+661.23%)
Joel Greenblatt 73,037 sh (+117.34%)
First Eagle Investment 1,056,150 sh (+55.71%)
David Dreman 31,197 sh (+10.27%)
Murray Stahl 35,121 sh (+9.55%)
Jeff Auxier 20,272 sh (+5.74%)
Scott Black 154,855 sh (+1.94%)
Robert Bruce 232,915 sh (unchged)
Tom Russo 86,718 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Lee Ainslie Sold Out
Mairs and Power 266,936 sh (-0.68%)
Dodge & Cox 33,255 sh (-2.92%)
NWQ Managers 1,526,806 sh (-3.59%)
Mario Gabelli 43,930 sh (-5.65%)
Ken Fisher 927,959 sh (-7.82%)
Larry Robbins 16,170,903 sh (-9.44%)
PRIMECAP Management 2,511,945 sh (-10.27%)
Pioneer Investments 2,286,962 sh (-15.35%)
» More
Q4 2015

ABBV Guru Trades in Q4 2015

Louis Moore Bacon 36,243 sh (New)
First Pacific Advisors 75,500 sh (New)
John Paulson 139,700 sh (New)
Joel Greenblatt 204,171 sh (+179.54%)
Murray Stahl 36,019 sh (+2.56%)
Ken Fisher 935,104 sh (+0.77%)
Dodge & Cox 33,255 sh (unchged)
Tom Russo 86,718 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Jeff Auxier 20,272 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
First Eagle Investment Sold Out
Mairs and Power 266,811 sh (-0.05%)
Mario Gabelli 40,600 sh (-7.58%)
David Dreman 26,267 sh (-15.80%)
Larry Robbins 13,544,815 sh (-16.24%)
Paul Tudor Jones 32,925 sh (-33.46%)
Pioneer Investments 1,150,074 sh (-49.71%)
NWQ Managers 754,413 sh (-50.59%)
PRIMECAP Management 1,165,045 sh (-53.62%)
Scott Black 40,798 sh (-73.65%)
Jim Simons 582,756 sh (-80.14%)
» More
Q1 2016

ABBV Guru Trades in Q1 2016

Murray Stahl 36,154 sh (+0.37%)
Samuel Isaly 1,225,000 sh (unchged)
Ken Fisher 743,284 sh (-20.51%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about AbbVie Inc

Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? The question that needs to be asked about AbbVie's demise is: What caused the earnings decline in the last five years after it went public?
Merck & Co. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are two very different companies and face very different situations when it comes to earnings and growth, not to mention one is significantly older than the other. From 2009 to 2010, Merck's earnings fell by 14 times what they previously were but have made a comeback and have leveled out while AbbVie has only been public since 2013 and in its short history as a public has seen its earnings plunge by 20.31% annually. Merck's earnings have stayed consistent since its earnings recovered from 26 cents in December 2010 to $3.74 currently. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.77
ABBV's P/E(ttm) is ranked higher than
71% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. ABBV: 18.77 )
Ranked among companies with meaningful P/E(ttm) only.
ABBV' s P/E(ttm) Range Over the Past 10 Years
Min: 9.86  Med: 20.04 Max: 63.84
Current: 18.77
9.86
63.84
Forward P/E 10.78
ABBV's Forward P/E is ranked higher than
71% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.86 vs. ABBV: 10.78 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.72
ABBV's PE(NRI) is ranked higher than
71% of the 539 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. ABBV: 18.72 )
Ranked among companies with meaningful PE(NRI) only.
ABBV' s PE(NRI) Range Over the Past 10 Years
Min: 9.85  Med: 20.04 Max: 63.95
Current: 18.72
9.85
63.95
Price/Owner Earnings (ttm) 15.92
ABBV's Price/Owner Earnings (ttm) is ranked higher than
81% of the 259 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.02 vs. ABBV: 15.92 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABBV' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.43  Med: 27.61 Max: 53.75
Current: 15.92
13.43
53.75
P/B 25.45
ABBV's P/B is ranked lower than
98% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. ABBV: 25.45 )
Ranked among companies with meaningful P/B only.
ABBV' s P/B Range Over the Past 10 Years
Min: 15.47  Med: 20.31 Max: 77.07
Current: 25.45
15.47
77.07
P/S 4.46
ABBV's P/S is ranked lower than
65% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. ABBV: 4.46 )
Ranked among companies with meaningful P/S only.
ABBV' s P/S Range Over the Past 10 Years
Min: 2.83  Med: 4.35 Max: 5.67
Current: 4.46
2.83
5.67
PFCF 14.56
ABBV's PFCF is ranked higher than
73% of the 192 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.79 vs. ABBV: 14.56 )
Ranked among companies with meaningful PFCF only.
ABBV' s PFCF Range Over the Past 10 Years
Min: 8.65  Med: 15.20 Max: 38.18
Current: 14.56
8.65
38.18
POCF 13.56
ABBV's POCF is ranked higher than
65% of the 251 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.79 vs. ABBV: 13.56 )
Ranked among companies with meaningful POCF only.
ABBV' s POCF Range Over the Past 10 Years
Min: 8.2  Med: 13.76 Max: 31.6
Current: 13.56
8.2
31.6
EV-to-EBIT 16.53
ABBV's EV-to-EBIT is ranked higher than
62% of the 525 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.51 vs. ABBV: 16.53 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 15.75 Max: 41
Current: 16.53
10.2
41
EV-to-EBITDA 14.85
ABBV's EV-to-EBITDA is ranked higher than
55% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.66 vs. ABBV: 14.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.6  Med: 13.90 Max: 33.1
Current: 14.85
8.6
33.1
Current Ratio 1.50
ABBV's Current Ratio is ranked lower than
73% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. ABBV: 1.50 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.04 Max: 2.82
Current: 1.5
1.22
2.82
Quick Ratio 1.34
ABBV's Quick Ratio is ranked lower than
65% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. ABBV: 1.34 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.86 Max: 2.65
Current: 1.34
1.06
2.65
Days Inventory 108.59
ABBV's Days Inventory is ranked higher than
53% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. ABBV: 108.59 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s Days Inventory Range Over the Past 10 Years
Min: 35.55  Med: 79.47 Max: 93.77
Current: 108.59
35.55
93.77
Days Sales Outstanding 72.61
ABBV's Days Sales Outstanding is ranked higher than
51% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.16 vs. ABBV: 72.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.53  Med: 78.73 Max: 93.3
Current: 72.61
71.53
93.3
Days Payable 118.31
ABBV's Days Payable is ranked higher than
73% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.22 vs. ABBV: 118.31 )
Ranked among companies with meaningful Days Payable only.
ABBV' s Days Payable Range Over the Past 10 Years
Min: 30.33  Med: 153.73 Max: 185.97
Current: 118.31
30.33
185.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.47
ABBV's Dividend Yield is ranked higher than
86% of the 565 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. ABBV: 3.47 )
Ranked among companies with meaningful Dividend Yield only.
ABBV' s Dividend Yield Range Over the Past 10 Years
Min: 0.85  Med: 2.86 Max: 3.84
Current: 3.47
0.85
3.84
Dividend Payout 0.64
ABBV's Dividend Payout is ranked lower than
78% of the 371 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. ABBV: 0.64 )
Ranked among companies with meaningful Dividend Payout only.
ABBV' s Dividend Payout Range Over the Past 10 Years
Min: 0.55  Med: 0.66 Max: 1.36
Current: 0.64
0.55
1.36
Forward Dividend Yield 3.71
ABBV's Forward Dividend Yield is ranked higher than
88% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. ABBV: 3.71 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.47
ABBV's Yield on cost (5-Year) is ranked higher than
75% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. ABBV: 3.47 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABBV' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.85  Med: 2.86 Max: 3.84
Current: 3.47
0.85
3.84
3-Year Average Share Buyback Ratio -0.70
ABBV's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 466 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.30 vs. ABBV: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABBV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.7  Med: -0.60 Max: 0
Current: -0.7
-0.7
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.03
ABBV's Price/Median PS Value is ranked higher than
62% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. ABBV: 1.03 )
Ranked among companies with meaningful Price/Median PS Value only.
ABBV' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.00 Max: 1.21
Current: 1.03
0.67
1.21
Earnings Yield (Greenblatt) (%) 6.02
ABBV's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. ABBV: 6.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABBV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 6.30 Max: 9.8
Current: 6.02
2.4
9.8

More Statistics

Revenue(Mil) $23777
EPS $ 3.32
Beta1.60
Short Percentage of Float1.35%
52-Week Range $45.45 - 71.60
Shares Outstanding(Mil)1611.24

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 25,134 27,498 29,136
EPS($) 4.87 5.70 6.50
EPS without NRI($) 4.87 5.70 6.50

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY, XPAR:SAN » details
Traded in other countries:ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
AbbVie Inc was incorporated in Delaware on April 10, 2012, and is a wholly owned subsidiary of Abbott. The company is a research-based biopharmaceutical company with portfolio of proprietary products including a broad line of adult and pediatric pharmaceuticals. The company discovers, develops, manufactures and sells proprietary pharmaceutical products. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications. AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across such important medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. AbbVie operates in one business segment-pharmaceutical products. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics.
» More Articles for ABBV

Headlines

Articles On GuruFocus.com
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
A Cheap Dividend Aristocrat Yielding Over 4% Mar 02 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Gilead, Johnson & Johnson or Roche? Feb 11 2016 
Glenview's Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Health Care Investor Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? Nov 12 2015 
Companies Return 12-Month Record Amount to Shareholders Sep 25 2015 
Baxalta Vs. AbbVie: Biopharma Spin-Off Battle Aug 20 2015 
JNJ – Should It Be In Your Portfolio? Aug 19 2015 

More From Other Websites
Charts are bullish for health care: Technician May 05 2016
[$$] Biotech Drug Knockoffs Bring Paltry Savings May 05 2016
Sohn Investment Conference 2016 – Full Wrap Up May 04 2016
Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in Q1, Biogen to Spin Off Hemophilia May 04 2016
Gilead Sciences: Feeling the Competitive Burn? May 04 2016
[$$] Quintiles and IMS jump on the M&A bandwagon May 03 2016
What Do Analysts Recommend for AbbVie? May 03 2016
How Does AbbVie’s Valuation Compare to Its Peers’? May 03 2016
ETF’s with exposure to AbbVie, Inc. : May 3, 2016 May 03 2016
AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance May 03 2016
Sohn Preview: What Will Larry Robbins, John Khoury & Carson Block Present Wednesday? May 03 2016
Gilead: What's Your Long Term Thesis? May 02 2016
Humira Continues to Be a Strong Growth Driver for AbbVie in 1Q16 May 02 2016
How Did AbbVie Perform in 1Q16? May 02 2016
AbbVie, Inc. :ABBV-US: Earnings Analysis: Q1, 2016 By the Numbers May 02 2016
ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Apr 29 2016
Worst may be over for embattled pharma Apr 29 2016
AbbVie (ABBV) Stock Price Target Hiked at Jefferies Apr 29 2016
Pharma stocks to bet on Apr 29 2016
AbbVie Gets European Medicines Agency's Positive Opinion For Its IMBRUVICA Apr 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK